Citadel Advisors
RVMD icon

Citadel Advisors’s Revolution Medicines RVMD Stock Holding History

Citadel Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.9M Sell
400,053
-902,308
-69% -$91.1M 0.01% 1594
2025
Q4 		$104M Buy
1,302,361
+122,276
+10% +$8.02M 0.02% 843
2025
Q3 		$55.1M Sell
1,180,085
-297,590
-20% -$11.7M 0.01% 1283
2025
Q2 		$54.4M Buy
1,477,675
+1,344,608
+1,010% +$51.7M 0.01% 1180
2025
Q1 		$4.71M Sell
133,067
-3,997
-3% -$162K ﹤0.01% 3973
2024
Q4 		$6M Sell
137,064
-143,873
-51% -$7.26M ﹤0.01% 3675
2024
Q3 		$12.7M Sell
280,937
-127,905
-31% -$5.57M ﹤0.01% 2569
2024
Q2 		$15.9M Sell
408,842
-179,246
-30% -$6.7M ﹤0.01% 2246
2024
Q1 		$19M Sell
588,088
-315,941
-35% -$9.36M ﹤0.01% 2123
2023
Q4 		$25.9M Buy
904,029
+657,571
+267% +$15.8M 0.01% 1766
2023
Q3 		$6.82M Buy
+246,458
New +$7.31M ﹤0.01% 3198
2023
Q2 		– Sell
-323
Closed -$7.92K – 15103
2023
Q1 		$7K Sell
323
-176,416
-100% -$4.34M ﹤0.01% 13767
2022
Q4 		$4.21M Buy
176,739
+152,687
+635% +$3.25M ﹤0.01% 4150
2022
Q3 		$474K Sell
24,052
-173,008
-88% -$3.8M ﹤0.01% 8572
2022
Q2 		$3.84M Buy
197,060
+130,258
+195% +$2.54M ﹤0.01% 4295
2022
Q1 		$1.7M Sell
66,802
-297,103
-82% -$6.47M ﹤0.01% 6448
2021
Q4 		$9.16M Buy
363,905
+270,483
+290% +$7.62M ﹤0.01% 3223
2021
Q3 		$2.57M Sell
93,422
-104,339
-53% -$3.04M ﹤0.01% 5741
2021
Q2 		$6.28M Sell
197,761
-919,431
-82% -$32.1M ﹤0.01% 3955
2021
Q1 		$51.3M Sell
1,117,192
-122,484
-10% -$5.49M 0.01% 1019
2020
Q4 		$49.1M Buy
1,239,676
+865,211
+231% +$34.2M 0.01% 956
2020
Q3 		$13M Sell
374,465
-47,471
-11% -$1.31M ﹤0.01% 1990
2020
Q2 		$13.3M Buy
421,936
+73,294
+21% +$2.3M ﹤0.01% 1896
2020
Q1 		$7.64M Buy
+348,642
New +$9.65M ﹤0.01% 2182

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Citadel Advisors's RVMD Position: Q1 2026 in Review

Citadel Advisors reduced its Revolution Medicines (RVMD) stake by 69% in Q1 2026, selling an estimated $91.1M and leaving 400,053 shares worth $38.9M. The position accounts for 0.01% of the portfolio, ranked #1594.

Citadel Advisors first reported a position in RVMD in Q1 2020 and has held it in 24 quarters since. The position peaked at $104M in Q4 2025. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • Citadel Advisors held 400,053 shares of Revolution Medicines worth $38.9M as of Q1 2026.
  • Citadel Advisors sold 902,308 Revolution Medicines shares in Q1 2026, an estimated $91.1M.
  • Revolution Medicines made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1594 holding.
  • Citadel Advisors first reported a position in Revolution Medicines in Q1 2020 and has held it in 24 quarters since.
  • Citadel Advisors's Revolution Medicines position peaked at $104M in Q4 2025.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.